Risk of Acute Kidney Injury and<i>Clostridioides difficile</i>Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin

Abstract

Piperacillin/tazobactam increased AKI risk, which was exacerbated by concurrent vancomycin. Cefepime and meropenem increased CDI risk relative to piperacillin/tazobactam. Clinicians should consider the risks and benefits of AP-BL when selecting empiric regimens. Further well-designed studies evaluating the global risks of AP-BL and patient specific characteristics that can guide empiric selection are needed.